文献速递眼底病与葡萄膜炎

抗VEGF治疗新生血管性年龄相关性黄斑变性后地图样萎缩发生与进展的Meta分析

GEOGRAPHIC ATROPHY INCIDENCE AND PROGRESSION AFTER INTRAVITREAL INJECTIONS OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS FOR AGE-RELATED MACULAR DEGENERATION: A Meta-Analysis.
PubMed 文献 · Retina · 2021-01-01

基线GA患病率为9.7%,随访末 pooled 发病率为30.5%。治疗总注射次数与GA发病率呈中度正相关(R²=0.30,P=0.01),每月治疗较按需治疗显著增加GA风险(RR=1.40,95%CI 1.21-1.61,P<0.001)。

要点

  • 抗VEGF治疗后GA pooled发病率为30.5%,基线患病率9.7%。
  • 每月治疗较按需治疗显著增加GA风险(RR=1.40,95%CI 1.21-1.61)。
  • 对侧眼GA、视网膜血管瘤样增生、玻璃膜疣和网状假性玻璃膜疣为GA危险因素。

核心结论

  • 抗VEGF药物的治疗频率和注射次数与新生血管性年龄相关性黄斑变性中GA的发生相关。

研究设计与样本

  • 系统检索Ovid MEDLINE、EMBASE和Cochrane CENTRAL从建库至2020年5月,纳入报告抗VEGF治疗后GA进展或发生的研究。

主要发现

  • 基线GA患病率为9.7%,随访结束时GA的pooled发病率为30.5%。
  • 平均总注射次数与末次随访GA发病率呈中度正线性相关(R²=0.30;P=0.01)。
  • 每月治疗相对于按需治疗与GA发生风险显著更高相关(相对危险度=1.40,95%置信区间=[1.21-1.61],P<0.001)。
  • GA发生的危险因素包括对侧眼GA、视网膜血管瘤样增生、玻璃膜疣和网状假性玻璃膜疣。

关键数值与推荐

  • 基线GA患病率为9.7%,随访末GA的pooled发病率为30.5%。
  • 每月治疗较按需治疗GA风险相对危险度=1.40(95%置信区间=[1.21-1.61],P<0.001)。
  • 平均总注射次数与GA发病率正相关(R²=0.30;P=0.01)。

临床怎么用

  • 临床抗VEGF治疗时应权衡治疗频率与GA风险,尤其对具有对侧眼GA、视网膜血管瘤样增生、玻璃膜疣或网状假性玻璃膜疣等危险因素的患者。

局限性

  • 未来研究应阐明危险因素、人群特征以及治疗和疾病进展对GA发生的相对贡献。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Geographic atrophy (GA) is a complication of advanced neovascular age-related macular degeneration that can lead to permanent vision loss. We sought to estimate the incidence and progression of GA after intravitreal injections of antivascular endothelial growth factor agents in eyes with neovascular age-related macular degeneration. METHODS: Ovid MEDLINE, EMBASE, and Cochrane CENTRAL were searched from inception to May 2020. Included studies reported on the progression or development of GA in eyes with neovascular age-related macular degeneration after antivascular endothelial growth factor therapy. RESULTS: Thirty-one articles and 4,609 study eyes (4,501 patients) were included. Eyes received a mean of 17.7 injections over 35.2 months. The prevalence of GA at baseline was 9.7%. The pooled incidence of GA was 30.5% at the end of follow-up. There was a positive, moderate linear correlation between the mean total number of injections and GA incidence at the final follow-up (R2 = 0.30; P = 0.01). Monthly treatment was associated with a significantly higher risk for GA development relative to pro re nata (relative risk = 1.40, 95% confidence interval = [1.21-1.61], P < 0.001). Risk factors for GA development included GA in the fellow eye, retinal angiomatous proliferation, drusen, and reticular pseudodrusen. CONCLUSION: We found an association between the frequency and number of treatments with antivascular endothelial growth factor agents and the development of GA in neovascular age-related macular degeneration. Future studies should clarify risk factors, population characteristics, and relative contributions of treatment and disease progression on GA development in this context.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Eshtiaghi A, Issa M, Popovic MM, et al. GEOGRAPHIC ATROPHY INCIDENCE AND PROGRESSION AFTER INTRAVITREAL INJECTIONS OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS FOR AGE-RELATED MACULAR DEGENERATION: A Meta-Analysis. Retina. 2021. PMID: 34101693. doi:10.1097/IAE.0000000000003207

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。